NCT04676334

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: pharmaand GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit. Participants in long-term follow-up (LTFU) in a parent study may also enroll in this study for continued data collection, as applicable based on parent study objectives.

Detailed description

Participants enrolled in this study are required to have completed an End-of-Treatment (EOT) Visit with associated assessments as specified in the Clovis-sponsored parent study (NCT01891344; NCT01968213; NCT02855944). Participants who are no longer receiving treatment and are in LTFU in the parent study (NCT02855944) may enroll into the LTFU portion of this study, as applicable based on parent study objectives, without repeating the EOT visit. The starting dose of rucaparib administered at initiation of this study will be the same as the last dose received in the parent study, or as deemed appropriate by the investigator and based on available dose strength tablets. The first treatment in the rollover study will begin at the next scheduled treatment visit following the EOT Visit in the parent study. Participants enrolled to receive continued rucaparib may be treated until disease progression, as assessed by the investigator, unacceptable toxicity, withdrawal of consent, death, loss to follow-up, or study closure by the sponsor. If a participant demonstrates disease progression per investigator assessment while receiving treatment with rucaparib but continues to derive clinical benefit, then continuation of treatment beyond progression is permitted based on investigator decision and participant consent. If a participant continues treatment post-progression, all study assessments should be continued per institutional standard of care. The participant should be discontinued from treatment once it is clear that no further clinical benefit can be achieved.

Conditions

• Metastatic Castration-Resistant Prostate Cancer
• Ovarian Cancer
• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer
• Other Solid Tumor

Interventions

Type	Name	Description
DRUG	Rucaparib	Rucaparib will be administered daily.

Timeline

• Start date: 2021-03-22
• Primary completion: 2023-03-08
• Completion: 2023-03-08
• First posted: 2020-12-21
• Last updated: 2024-05-07
• Results posted: 2024-05-07

Locations

25 sites across 6 countries: Canada, Israel, Italy, Poland, Russia, United Kingdom

Regulatory

• FDA-regulated drug study